Form 4: Immunome Director Sandra Swain Receives Stock Option Grant

Director Sandra M. Swain was granted 9,897 stock options in Immunome, Inc. as part of standard equity compensation.

Summary

• Director Sandra M. Swain received a grant of 9,897 stock options for Immunome, Inc. (IMNM) common stock.
• The options have an exercise price of $18.16 per share.
• The grant was issued on June 10, 2026, and expires on June 9, 2036.
• The options vest in four equal quarterly installments over one year, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Equity-based compensation aligns the interests of the director with those of shareholders.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is subject to the director's continuous service with the company.

Future Outlook

The options vest quarterly over one year, indicating a short-term retention incentive for the director.

Industry Context

StockSavvy.ai notes that director equity grants are standard practice in the biotechnology sector to attract and retain board expertise, though they are generally neutral regarding immediate share price movement.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard corporate governance practices for mid-cap biotechnology firms.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options in four equal quarterly installments starting from June 10, 2026.

Key Dates

Keywords

Immunome, IMNM, Form 4, Insider Trading, Stock Options, Director Compensation